Dr. Paul Kemp of Intercytex to speak at ‘Future Advances in Regenerative Medicine’ meeting
Claire Morgan
Wednesday, 30 April 2008 18:01 UTC
Dr Paul Kemp, Founder and Chief Scientific Officer of UK-based company Intercytex will be speaking at our ‘Future Advances in Regenerative Medicine’ meeting on June 13th .. He will be discussing his experience of building and growing a viable Regenerative Medicine company and how strategies will be adapted to the changing scientific and regulatory environment in the future.
The agenda of this meeting features exciting talks from many other stem cell researchers:
Introduction by the Chair: Dr Stephen Minger, Kings College, UK- Director of the Stem Cell Biology Laboratory and a Senior Lecturer in the Wolfson Centre for Age Related Diseases at King’s College London.
Updates on Regenerative Medicine: Nanobiomaterials and Stem Cells
Professor Nureddin Ashammakhi, Keele University, UK
Limbal epithelial stem cell therapy for the treatment of blinding ocular surface disease.
Dr Julie T Daniels, Director, Moorfields Eye Hospital Cells for Sight Tissue Bank, UK
Stem Cell Transplantation Supports the Repair of Injured Olfactory Neuroepithelium after Permanent Damage
Professor Roberto P. Revoltella, University of Pisa, Italy
Differentiation of embryonic stem cells towards germ cells
Dr Lyle Armstrong, Centre For Stem Cell Biology & Developmental Genetics International Centre For Life, UK
Interaction of Grafted Neural Precursor Cells with Purkinje Cells in a SCA1 Mouse Model
Satyan Chintawar, Laboratory of Experimental Neurology, ULB, Brussels, Belgium
Neural transplantation for Parkinson’s and Huntington’s disease: stem cells and beyond
Dr Rike Zietlow, Cardiff University, UK
The Role of the UK Stem Cell Bank in Cellular Therapy
Dr Charles Hunt, UK Stem Cell Bank, National Institute for Biological Standards and Control
To book a place please click here
-
Replies
-
Julian Hitchcock (Senior Solicitor, Life Sciences, Mills & Reeve LLP) will be discussing new developments in stem cell patenting at this meeting. His talk will be entitled ‘A new IP landscape for stem cells?’
Here are a few words from Julian:
“Times are changing on the IP front. The European Patent Office is due to hand down its decision on the WARF hESC patent application by the end of June. What might be the implications of the decision? What will be the impact of innovations in induced pluripotency?”
Julian Hitchcock is an expert on cell and tissue law, whose involvement began in the 1980s, following an education in medicine. Having qualified as a solicitor at Wragge & Co. in 1998, Julian took the Bristol University IP Diploma in 2000 and practised for Blake Dawson Waldron in Melbourne, where he conducted patent litigation on leading products. His clients include life science companies, research-orientated universities and health organisations such as NHSBT. An earnest advocate of stem cell research and translation, Julian is a founding director of the East of England Stem Cell Network. He joined Mills & Reeve in 2004.
To book a place at this meeting, please click here
-
